α-(2,6-dimethyl-4-carboxyphenyl)-2-methyl-5-(1-imidazolyl)-benzenemethanol | 107433-19-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: α-(2,6-dimethyl-4-carboxyphenyl)-2-methyl-5-(1-imidazolyl)-benzenemethanol
• 英文别名: 4-[α-hydroxy-2-methyl-5-(1-imidazolyl)-benzyl]-3,5-dimethylbenzoic acid；4-[α-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoic acid；Y-20811 free acid；4-[hydroxy-(5-imidazol-1-yl-2-methylphenyl)methyl]-3,5-dimethylbenzoic acid
• CAS: 107433-19-2
• 化学式: C₂₀H₂₀N₂O₃
• 分子量: 336.39
• InChiKey: QSAHHFJAWATNBG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  75.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  α-(2,6-dimethyl-4-carboxyphenyl)-2-methyl-5-(1-imidazolyl)-benzenemethanol 、 sodium hydroxide 生成 4-(alpha-Hydroxy-5-(1-imidazolyl)-2-methylbenzyl)-3,5-dimethylbenzoic acid
  参考文献：
  名称：

  TSURUDA, MINEO;SHIOTSUKI, TAKAKO;MATSUMOTO, TAKASHI;OE, TAKANORI, YAKUGAKU DZASSI, 109,(1989) N, S. 26-32

  摘要：

  DOI：
• 作为产物：
  描述：

  4-[5-(imidazol-1-yl)-2-methylbenzoyl]-3,5-dimethylbenzoic acid 在 sodium hydroxide 、 sodium borohydrid 作用下， 以 水 为溶剂， 生成 α-(2,6-dimethyl-4-carboxyphenyl)-2-methyl-5-(1-imidazolyl)-benzenemethanol
  参考文献：
  名称：

  Imidazole derivatives

  摘要：

  .alpha.-(2,6-二甲基-4-羧基苯基)-2-甲基-5-(1-咪唑基)-苯甲醇，其药学上可接受的金属盐形式，其酸加成盐形式，其氨基酸加成盐形式，其水合物形式以及其混合物。这些化合物具有抑制血栓素A.sub.2生物合成的活性，抑制血小板聚集的活性，扩张血管的活性以及对肝脏疾病的保护作用。

  公开号：

  US04661603A1

文献信息

• METHOD OF ASYMMETRICALLY REDUCING 4- 5-(IMIDAZOL-1-YL)-2-MET HYLBENZOYL -3,5-DIMETHYL-BENZOIC ACID OR ESTER THEREOF
  申请人：Mitsubishi Pharma Corporation

  公开号：EP1719764A1

  公开（公告）日：2006-11-08

  The invention relates to a method of producing an optically active 4-[hydroxy[5-(imidazol-1-yl)-2-methylphenyl]methyl]-3,5-dimethylbenzoic acid or an ester thereof, which includes reacting 4-[5-(imidazol-1-yl)-2-methylbenzoyl]-3,5-dimethylbenzoic acid or an ester thereof with a silane agent in the presence of a particular zinc compound and an optically active diamine compound.

  本发明涉及一种制备光学活性4-[羟基[5-(咪唑-1-基)-2-甲基苯基]甲基]-3,5-二甲基苯甲酸或其酯的方法，包括在特定的锌化合物和光学活性二胺化合物存在下，将4-[5-(咪唑-1-基)-2-甲基苯甲酰基]-3,5-二甲基苯甲酸或其酯与硅烷试剂反应。
• Method of asymmetrically reducing 4-[5-(imidazol-1-yl)-2-methylbenzoyl]-3,5- dimethylbenzoic acid or ester thereof
  申请人：Ushio Hiroyuki

  公开号：US20070161803A1

  公开（公告）日：2007-07-12

  The invention relates to a method of producing an optically active 4-[hydroxy[5-(imidazol-1-yl)-2-methylphenyl]methyl]-3,5-dimethylbenzoic acid or an ester thereof, which includes reacting 4-[5-(imidazol-1-yl)-2-methylbenzoyl]-3,5-dimethylbenzoic acid or an ester thereof with a silane agent in the presence of a particular zinc compound and an optically active diamine compound.

  本发明涉及一种制备光学活性4-[羟基[5-(咪唑-1-基)-2-甲基苯基]甲基]-3,5-二甲基苯甲酸或其酯的方法，包括在特定锌化合物和光学活性二胺化合物的存在下，将4-[5-(咪唑-1-基)-2-甲基苯甲酰基]-3,5-二甲基苯甲酸或其酯与硅烷试剂反应。
• MEDICAL MATERIAL AND PROCESS FOR PRODUCING THE SAME
  申请人：OTSUKA PHARMACEUTICAL FACTORY, INC.

  公开号：EP0665023A1

  公开（公告）日：1995-08-02

  A medical material comprising a polymer or copolymer of a polar vinyl derivative and containing an antithrombocytic agent. Since it can release the antithrombocytic agent in an effective concentration for long, it has a high anticoagulant effect and the effect of preventing platelet loss by activating the same.

  一种医用材料，由极性乙烯基衍生物的聚合物或共聚物组成，并含有抗血栓形成剂。由于它能长期释放有效浓度的抗血栓形成剂，因此具有很高的抗凝血效果，并能通过激活血小板防止其流失。
• METHOD OF INHIBITING BLOOD COAGULATION DURING EXTRACORPOREAL BLOOD CIRCULATION AND DEVICE FOR RELEASING ANTITHROMBOTIC DRUG USED THEREIN
  申请人：OTSUKA PHARMACEUTICAL FACTORY, INC.

  公开号：EP0704223A1

  公开（公告）日：1996-04-03

  A method of inhibiting the coagulation of blood during the extracorporeal circulation thereof by bringing a member for releasing an antithrombotic drug, prepared by dispersing a difficulty water-soluble antithrombotic drug in a macromolecular material, into contact with the circulating blood. A device for releasing an antithrombotic drug to be used in the above method comprises either the drug releasing member contained in a vessel provided with blood inlet and outlet ports at the respective ends thereof or the drug releasing member constituting at least the inner wall surface of the vessel. As the antithrombotic agent can be released sustainedly from the drug releasing member, the blood coagulation in the blood circuit can be inhibited as a result of the contact of the blood with the member during the extracorporeal circulation.

  一种在体外循环过程中抑制血液凝固的方法，其方法是将通过在高分子材料中分散难溶于水的抗血栓药物而制备的释放抗血栓药物的部件与循环血液接触。在上述方法中使用的抗血栓药物释放装置包括：药物释放部件装在一个容器中，容器的两端分别设有血液入口和出口；或者药物释放部件至少构成容器的内壁表面。由于抗血栓药物可从药物释放部件中持续释放，在体外循环过程中，血液与该部件的接触可抑制血路中的血液凝固。
• PREVENTIVES/REMEDIES FOR COMPLICATIONS OF DIABETES
  申请人：YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.

  公开号：EP0881218A1

  公开（公告）日：1998-12-02

  Preventives/remedies for complications of diabetes containing as the active ingredient 4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid, optical isomers thereof or pharmaceutically acceptable salts thereof; and a method for preventing or treating complications of diabetes by administering the above compounds in an efficacious dose. These drugs are useful in the prevention and treatment of complications of diabetes such as diabetic neuropathy, nephropathy, ocular disorders and arterial sclerosis. Moreover, they can exhibit long lasting effects even in an extremely small dose, which makes it possible to take the drugs only once a day.

  预防/治疗糖尿病并发症的药物，其活性成分为 4-[α-羟基-2-甲基-5-(1-咪唑基)苄基]-3,5-二甲基苯甲酸、其光学异构体或其药学上可接受的盐；以及通过以有效剂量给药上述化合物来预防或治疗糖尿病并发症的方法。这些药物可用于预防和治疗糖尿病并发症，如糖尿病神经病变、肾病、眼部疾病和动脉硬化。此外，这些药物即使剂量极小，也能产生持久的疗效，因此每天只需服用一次即可。